Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

May Abdo-matkiwsky (NPI 1306887708)

Field	Value
Entity Type	Individual
Organization	May Abdo-matkiwsky
Address	89 Sparta Ave
City	Sparta
State	NJ
ZIP	07871
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 9, 2006

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

This provider is effectively single-payer in the available claims data: reported total Medicare revenue is $2.6M and there is no Medicaid billing on file, so Medicare accounts for the entirety of recorded public-payer activity for this NPI. That concentration limits visibility into Medicaid-facing volumes and suggests the provider’s public-payer footprint is driven almost entirely by Medicare beneficiaries.

Revenue is highly concentrated in a small set of drugs and E/M services: the precomputed top‑3 Medicare codes (J9271, 99214, J0897) account for 71.4% of this provider’s total Medicare revenue. J9271 (pembrolizumab) alone represents $1.4M or 54.8% of Medicare revenue, indicating a dominant single-code dependency within the revenue mix.

Clinical/service line profile aligns with a high-volume oncology infusion and follow-up practice: the dominance of J9271 (pembrolizumab) and J0897 (denosumab), combined with chemotherapy administration codes such as 96413 (862 claims, $102.6K) and infusion add-on codes like 96415 (344 claims, $8.9K) and 96417 (232 claims, $13.9K), indicates routine administration of immunotherapy and systemic cancer therapies in the outpatient/infusion setting. Frequent ordering of monitoring labs is consistent with this model, as 85025 (CBC) appears with 3K claims and $24.2K revenue.

The provider shows outsized office-visit throughput for established patients: 99214 has 2.2K claims, $233.1K revenue (9.3% of Medicare revenue) and is described as an "extreme outlier" (rank #889 of 479517, 100th percentile). This suggests a heavy volume of medium-complexity longitudinal ambulatory care visits that accompany the infusion/oncology service line.

Competitive standing varies by code but shows multiple high-percentile placements nationally: J9271 ranks #102 of 1841 providers (94th percentile; "notably above typical national volume"), 96413 ranks #133 of 7514 (98th percentile; "notably above typical national volume"), and 96367 ranks #42 of 4032 (99th percentile; "extreme outlier"). These rankings indicate the provider operates well above typical national volumes for several infusion- and chemotherapy-related services, positioning them as a relatively large feeder of specific oncology treatments.

Biosimilar utilization is evident in the top revenue mix, reflecting routine use of biosimilar agents in infusion practice: Q5118 (bevacizumab-bvzr) generated $105.1K (4.2% of Medicare revenue), Q5111 (pegfilgrastim-cbqv) generated $96.8K (3.9%), and Q5119 (rituximab-pvvr) generated $73.9K (2.9%). These codes rank in mid-to-high percentiles among small national cohorts (for example, Q5118 rank #27 of 161, 84th percentile), suggesting adoption of biosimilar products alongside branded therapies.

Operational risk and strategic sensitivity are concentrated around a few high-impact codes: with J9271 comprising $1.4M (54.8% of Medicare revenue) and the top three codes making up 71.4% of total Medicare revenue, changes in utilization patterns, payer coverage, or pricing for pembrolizumab and associated office visits could materially affect practice revenue. This concentration also implies limited diversification across payers, since Medicaid activity is not present in the filing.

Tenure and market presence are established: the NPI was enumerated on 2006-06-09 (~20 years ago), which supports an interpretation of an established practice or long-standing professional billing history; coupled with multiple high-percentile procedure rankings, this tenure aligns with sustained high-volume oncology service delivery.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

53 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	32,000	$40	$1.4M
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,220	$110	$233.1K
J0897	Injection, denosumab, 1 mg	10,200	$20	$183.6K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	4,570	$20	$105.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	860	$120	$102.6K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	890	$110	$96.8K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	3,360	$20	$73.9K
J1437	Injection, ferric derisomaltose, 10 mg	2,900	$20	$49.3K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	1,290	$30	$33.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	220	$150	$32.4K

Showing 1–10 of 53

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 53 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

May Abdo-matkiwsky — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

53 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	50	10,650	$40	$580.7K
Q5118	1	10	4,570	$20	$104.8K
Q5119	4	10	3,620	$20	$98.7K
J0897	37	380	3,060	$20	$87.8K
J1437	18	30	4,000	$20	$78.6K
Q5111	11	50	580	$110	$76.6K
J1439	49	70	34,880	$1	$36.5K
J3490	9	120	70	$230	$30.2K
96413	7	230	190	$110	$26.6K
85025	17	750	120	$10	$24.2K

Showing 1–10 of 53

Related Providers

Other providers that share a Tax Identification Number (TIN) with May Abdo-matkiwsky, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Glen Gejerman	NJ	Radiation Oncology Physician	$6.5M	$0
Bhavesh Balar	NJ	Hematology & Oncology Physician	$4.2M	$0
Kenneth Nahum	NJ	Hematology & Oncology Physician	$3.2M	$0
Frederick Smith	MD	Medical Oncology Physician	$2.7M	$0
Denis Fitzgerald	NJ	Hematology & Oncology Physician	$2.3M	$0
Gurpreet Lamba	VT	Hematology & Oncology Physician	$2.2M	$0
Jeffrey Silberberg	NJ	Hematology & Oncology Physician	$2M	$0
Roel Galope	NJ	Specialist	$1.9M	$0
Victor Aviles	MA	Hematology & Oncology Physician	$1.8M	$0
James Xu	MD	Hematology & Oncology Physician	$1.6M	$0

Nearby Providers

Other providers in the same ZIP code as May Abdo-matkiwsky, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Broadstep Academy-new Jersey, Inc.	NJ	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$137.1M
Jumana Chatiwala	NJ	Internal Medicine Physician	$1.3M	$0
Kathy Lo	NJ	Radiation Oncology Physician	$1.2M	$0
Specialty Surgical Center LLC	NJ	Clinic/Center	$739.7K	$0
Anthony Papadopoulos	NJ	Dermatology Physician	$505K	$0
Hector Cordero	NJ	Diagnostic Radiology Physician	$491.7K	$0
Premier Health Associates, LLC	NJ	Clinic/Center	$440.7K	$0
Alex Shin	NJ	Orthopaedic Surgery Physician	$376.6K	$0
Haroon Sarwar	NJ	Rheumatology Physician	$363.9K	$0
Frederick Corio	NJ	Diagnostic Radiology Physician	$338K	$0

May Abdo-matkiwsky — Billing Profile & Reimbursement Data

Sign up for May Abdo-matkiwsky — Billing Profile & Reimbursement Data policy alerts

May Abdo-matkiwsky — Billing Profile & Reimbursement Data

Sign up for May Abdo-matkiwsky — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References